Key Patient Considerations for the Utilization of Intravenous and Subcutaneous Therapies : Episode 3
Clinical Considerations for the Utilization of Intravenous vs. Subcutaneous Biologics
Dr. Zouzoulas discusses key patient considerations to consider when deciding on an intravenous or subcutaneous biologic.
EP: 1.Indication and Practical Utilization of IV and Subcutaneous Biologics
EP: 2.Key Consideration and Concerns Around IV and Subcutaneous Biologic Use
Now Viewing
EP: 3.Clinical Considerations for the Utilization of Intravenous vs. Subcutaneous Biologics
EP: 4.Key Patient Factors in Determining an Optimal Biologic Therapy
EP: 5.Incorporating Patient Perspectives When Determining a Route of Administration for Biologic Therapies
EP: 6.Future Predictions for Intravenous and Subcutaneous Biologics
EP: 7.Overall Experience With Intravenous Biologics
EP: 8.Clinical Insights With Subcutaneous Biologics
EP: 9.Innovations Associated With IV Biologics
EP: 10.Exciting Developments With Subcutaneous Biologics
EP: 11.Positioning Intravenous and Subcutaneous Biologics
EP: 12.Adherence With Intravenous Biologics
EP: 13.Billing With Intravenous and Subcutaneous Therapies
EP: 14.Evaluating Efficacy Between Intravenous and Subcutaneous Biologics
EP: 15.Cost Considerations With Intravenous and Subcutaneous Biologics
EP: 16.Patient Experience With Intravenous and Subcutaneous Therapies
Video content above is prompted by the following questions:
- How do you position IV and subcutaneous biologics in your treatment algorithms? Which patients are ideal for IV and which patients are ideal for subQ?
- Patients have more frequent contact with physicians with IV route of administration vs. subQ. Do you think this fosters better relationships and increases adherence?
Recent Videos
Related Content
Value-Based Decision-Making in Metastatic Breast Cancer
September 16th 2021Article
In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Read More
